NasdaqGS - Nasdaq Real Time Price • USD
Akero Therapeutics, Inc. (AKRO)
As of 3:09 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 8 | 7 |
| Avg. Estimate | -0.94 | -0.98 | -3.94 | -4.23 |
| Low Estimate | -1.15 | -1.17 | -4.64 | -4.82 |
| High Estimate | -0.82 | -0.86 | -3.48 | -3.69 |
| Year Ago EPS | -0.6 | -0.71 | -2.89 | -3.94 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 6 | 6 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.63 | -0.68 | -0.86 | -0.95 |
| EPS Actual | -0.6 | -0.71 | -0.99 | -0.9 |
| Difference | 0.03 | -0.03 | -0.13 | 0.05 |
| Surprise % | 4.80% | -4.40% | -15.10% | 5.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.94 | -0.98 | -3.94 | -4.23 |
| 7 Days Ago | -0.97 | -1.01 | -3.89 | -4.25 |
| 30 Days Ago | -1 | -1.04 | -3.97 | -4.33 |
| 60 Days Ago | -1 | -1.04 | -3.97 | -4.33 |
| 90 Days Ago | -0.95 | -0.99 | -3.54 | -4.23 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 3 | 3 | 3 | 3 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | AKRO | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -56.70% | -- | -- | 8.00% |
| Next Qtr. | -38.00% | -- | -- | 12.40% |
| Current Year | -36.30% | -- | -- | 5.60% |
| Next Year | -7.40% | -- | -- | 12.60% |
| Next 5 Years (per annum) | -14.60% | -- | -- | 11.14% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Evercore ISI Group: Outperform to Outperform | 5/15/2024 |
| Maintains | Canaccord Genuity: Buy to Buy | 5/13/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/13/2024 |
| Maintains | UBS: Buy to Buy | 3/5/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/5/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/1/2024 |
Related Tickers
ETNB 89bio, Inc.
8.99
+4.17%
STOK Stoke Therapeutics, Inc.
16.03
+15.29%
MDGL Madrigal Pharmaceuticals, Inc.
231.38
+5.14%
CABA Cabaletta Bio, Inc.
12.74
+3.16%
PLRX Pliant Therapeutics, Inc.
15.40
+0.85%
ALEC Alector, Inc.
5.39
-0.92%
RVMD Revolution Medicines, Inc.
39.93
+1.32%
BDTX Black Diamond Therapeutics, Inc.
4.8800
+0.21%
VTYX Ventyx Biosciences, Inc.
4.9550
+4.76%
IMVT Immunovant, Inc.
30.71
+0.03%